ORGO - Organogenesis Holdings reports Q2 earnings; narrows FY22 guidance

• Organogenesis Holdings press release ( NASDAQ: ORGO ): Q2 GAAP EPS of $0.07.
• Revenue of $121.4M (-1.5% Y/Y).
• Adjusted EBITDA of $18.6M for the second quarter of 2022, compared to Adjusted EBITDA of $25.1M for the second quarter of 2021, a decrease of $6.5M.
• Fiscal Year 2022 Guidance : Net revenue of between $465 million and $490 million vs. consensus of $494.15M, representing a decrease of approximately 1% to an increase of 5% year-over-year, and 2% to 7% on an adjusted basis, as compared to net revenue of $467.4 million for the year ended December 31, 2021.
• Net income in a range of approximately $26 million to $36 million and adjusted net income in a range of approximately $33 million to $43 million.
• EBITDA in a range of approximately $49 million to $63 million and Adjusted EBITDA in a range of approximately $60 million to $74 million.

For further details see: